Projects per year
Abstract
Genetic alterations in the INK4a/ARF (or CDKN2A) locus have been reported in many cancer types, including melanoma; head and neck squamous cell carcinomas; lung, breast, and pancreatic cancers. In melanoma, loss of function CDKN2A alterations have been identified in approximately 50% of primary melanomas, in over 75% of metastatic melanomas, and in the germline of 40% of families with a predisposition to cutaneous melanoma. The CDKN2A locus encodes two critical tumor suppressor proteins, the cyclin‐dependent kinase inhibitor p16INK4a and the p53 regulator p14ARF. The majority of CDKN2A alterations in melanoma selectively target p16INK4a or affect the coding sequence of both p16INK4a and p14ARF. There is also a subset of less common somatic and germline INK4a/ARF alterations that affect p14ARF, while not altering the syntenic p16INK4a coding regions. In this review, we describe the frequency and types of somatic alterations affecting the CDKN2A locus in melanoma and germline CDKN2A alterations in familial melanoma, and their functional consequences in melanoma development. We discuss the clinical implications of CDKN2A inactivating alterations and their influence on treatment response and resistance.
Original language | English |
---|---|
Article number | 1447 |
Pages (from-to) | 1-17 |
Number of pages | 17 |
Journal | Biomolecules |
Volume | 10 |
Issue number | 10 |
DOIs | |
Publication status | Published - 1 Oct 2020 |
Bibliographical note
Copyright the Author(s) 2020. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.Keywords
- CDKN2A
- INK4a/ARF
- Melanoma
- P14
- P16
- Tumor suppressor proteins
Fingerprint
Dive into the research topics of 'Genetic alterations in the ink4a/arf locus: effects on melanoma development and progression'. Together they form a unique fingerprint.-
Molecular determinants of risk, progression and treatment response in melanoma
Kefford, R., Thompson, J., Hersey, P., Mann, G., Scolyer, R., Hayward, N. & Long, G.
1/01/16 → …
Project: Research
-
Acquired resistance to PD1 inhibition in melanoma
Rizos, H., Carlino, M., Kefford, R., Zhang, X. D., Menzies, A. M., Long, G., McGuire, H., Yang, J., Scolyer, R. & De St Groth, B. F.
1/01/17 → 31/12/21
Project: Research
-
Manipulating oncogene addiction and immunity in the treatment of melanoma
1/01/16 → 31/12/20
Project: Research